Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.

MLA

VandenBussche, Christopher J., et al. “Alternative Lengthening of Telomeres and ATRX/DAXX Loss Can Be Reliably Detected in FNAs of Pancreatic Neuroendocrine Tumors.” Cancer Cytopathology, vol. 125, no. 7, July 2017, pp. 544–51. EBSCOhost, https://doi.org/10.1002/cncy.21857.

APA

VandenBussche, C. J., Allison, D. B., Graham, M. K., Charu, V., Lennon, A. M., Wolfgang, C. L., Hruban, R. H., & Heaphy, C. M. (2017). Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. Cancer Cytopathology, 125(7), 544–551. https://doi.org/10.1002/cncy.21857

Chicago

VandenBussche, Christopher J., Derek B. Allison, Mindy K. Graham, Vivek Charu, Anne Marie Lennon, Christopher L. Wolfgang, Ralph H. Hruban, and Christopher M. Heaphy. 2017. “Alternative Lengthening of Telomeres and ATRX/DAXX Loss Can Be Reliably Detected in FNAs of Pancreatic Neuroendocrine Tumors.” Cancer Cytopathology 125 (7): 544–51. doi:10.1002/cncy.21857.